Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.
Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.
Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.
Taysha Gene Therapies (Nasdaq: TSHA) has announced significant executive leadership changes as of December 16, 2022. Sean P. Nolan, formerly Chair of the Board, is now the Chief Executive Officer, succeeding RA Session II, who remains on the Board. Dr. Sukumar Nagendran has been appointed President and Head of R&D. Both leaders aim to advance clinical programs in Giant Axonal Neuropathy (GAN) and Rett syndrome and strengthen Taysha's partnership with Astellas. The company plans to host an investor call in January to discuss feedback from the FDA regarding GAN.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the JMP Securities Hematology and Oncology Summit from December 6-7, 2022. The company's President and CEO, RA Session II, will engage in a fireside chat on December 7 at 3:40 PM ET with Dr. Silvan Turkan from JMP Securities. A webcast of the discussion will be accessible on Taysha's corporate website, with an archived version available for 90 days. Taysha is committed to developing AAV-based gene therapies for monogenic CNS diseases, aiming to translate innovative treatments from bench to bedside.
Taysha Gene Therapies (TSHA) announced a $50 million strategic investment from Astellas Pharma to support the development of TSHA-120 for giant axonal neuropathy (GAN) and TSHA-102 for Rett syndrome. This investment, alongside a recent public offering that raised $28 million, extends the company's cash runway into Q1 2024. Taysha will provide a regulatory update on TSHA-120 in January 2023 and expects preliminary clinical data for TSHA-102 in H1 2023. For Q3 2022, R&D expenses were $16.4 million, with a net loss of $26.3 million, showing significant cost reductions compared to the previous year.
Taysha Gene Therapies (Nasdaq: TSHA) will announce its third-quarter financial results on November 8, 2022, at 8:00 AM ET, alongside a corporate update conference call. The company focuses on developing AAV-based gene therapies for monogenic diseases of the central nervous system. This pivotal-stage organization aims to translate treatments quickly from bench to bedside, leveraging a partnership with UT Southwestern Gene Therapy Program.
Taysha Gene Therapies (Nasdaq: TSHA) announced the pricing of a public offering of 14,000,000 shares at $2.00 each, potentially raising approximately $28.0 million in gross proceeds before underwriting costs. Additionally, the underwriter has a 30-day option for 2,100,000 extra shares. The offering is expected to close by October 31, 2022, pending standard conditions. Goldman Sachs is the sole book-runner for this transaction. Proceeds will support Taysha's mission to develop AAV-based gene therapies for CNS diseases.
Taysha Gene Therapies (Nasdaq: TSHA) announced plans for a public offering of $30 million in common stock, subject to market conditions. The company will grant underwriters a 30-day option to purchase up to an additional 15% of the shares. Goldman Sachs & Co. LLC is the sole book-runner for the offering. This move aims to bolster Taysha's resources for developing AAV-based gene therapies for CNS diseases. The offering follows a previously filed shelf registration statement with the SEC, effective since October 14, 2021.
Taysha Gene Therapies (Nasdaq: TSHA) announced a conference call on October 25, 2022, at 8:00 AM ET to discuss Astellas Pharma’s strategic investment in two gene therapy programs: TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN). This investment aims to bolster the development of AAV-based therapies targeting rare and large patient populations suffering from monogenic diseases of the central nervous system (CNS). For details, visit Taysha's webcast.
Taysha Gene Therapies has announced a strategic partnership with Astellas Pharma, securing a $50 million investment for a 15% ownership stake. This collaboration aims to advance Taysha's innovative gene therapies, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN), addressing serious unmet medical needs. Astellas will acquire exclusive licensing options for these therapies and gain rights related to any change of control at Taysha, along with a Board observer seat. This investment is expected to enhance Taysha's R&D and commercialization efforts in gene therapy.
Astellas Pharma and Taysha Gene Therapies announced a strategic investment of $50 million, acquiring a 15% stake in Taysha while gaining exclusive licensing options for two gene therapy candidates, TSHA-102 and TSHA-120. This collaboration aims to develop therapies for Rett syndrome and Giant Axonal Neuropathy (GAN), addressing significant unmet medical needs. Astellas will also receive a Board observer seat and certain rights regarding potential control changes at Taysha, enhancing their gene therapy capabilities in the central nervous system domain.
Summary not available.